Averitas Company Profile

What is the competitive landscape for AVERITAS

AVERITAS has two approved drugs.

There are four US patents protecting AVERITAS drugs.

There are one hundred and thirty-seven patent family members on AVERITAS drugs in forty-nine countries and eighteen supplementary protection certificates in fifteen countries.

Summary for Averitas

International Patents:	137
US Patents:	4
Tradenames:	2
Ingredients:	2
NDAs:	2

Drugs and US Patents for Averitas

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Averitas	QUTENZA	capsaicin	PATCH;TOPICAL	022395-001	Nov 16, 2009		RX	Yes	Yes	9,226,903		Y
Averitas	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-001	Sep 16, 2014		RX	Yes	No	9,012,469		Y	Y
Averitas	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-002	Sep 16, 2014		RX	Yes	Yes	7,786,133		Y	Y
Averitas	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-002	Sep 16, 2014		RX	Yes	Yes	9,012,469		Y	Y
Averitas	QUTENZA	capsaicin	PATCH;TOPICAL	022395-001	Nov 16, 2009		RX	Yes	Yes	8,821,920		Y

Expired US Patents for Averitas

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Averitas	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-001	Sep 16, 2014	8,617,530
Averitas	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-002	Sep 16, 2014	8,067,431
Averitas	QUTENZA	capsaicin	PATCH;TOPICAL	022395-001	Nov 16, 2009	10,034,841
Averitas	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-001	Sep 16, 2014	7,056,500
Averitas	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-002	Sep 16, 2014	7,056,500

Paragraph IV (Patent) Challenges for AVERITAS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	12.5 mg and 25 mg		2018-09-17

International Patents for Averitas Drugs

Country	Patent Number	Estimated Expiration
South Korea	20060126714
Eurasian Patent Organization	018427
South Africa	200605763
Israel	181337
South Africa	200506462

Supplementary Protection Certificates for Averitas Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1694363	C 2015 022	Romania		PRODUCT NAME: NALOXEGOL SI SARURILE SALE ACCEPTABILE FARMACEUTIC, IN SPECIAL SAREA OXALAT A NALOXEGOLULUI; NATIONAL AUTHORISATION NUMBER: EU/1/14/962; DATE OF NATIONAL AUTHORISATION: 20141208; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/962; DATE OF FIRST AUTHORISATION IN EEA: 20141208
1694363	300737	Netherlands		PRODUCT NAME: NALOXEGOL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER NALOGEXOLOXALAAT; REGISTRATION NO/DATE: EU/1/14/962 20141210
1694363	122015000037	Germany		PRODUCT NAME: NALOXEGOL ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/962 20141208
1694363	2015/024	Ireland		PRODUCT NAME: NALOXEGOL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE OXALATE SALT OF THE ALPHA-EPIMER OF NALOXEGOL; REGISTRATION NO/DATE: EU/1/14/962 20141208
1694363	CR 2015 00028	Denmark		PRODUCT NAME: OXYLATSALT AF NALOXEGOL; REG. NO/DATE: EU/1/14/962 20141210

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Averitas

Pharmaceutical Competitive Landscape Analysis: Averitas – Market Position, Strengths & Strategic Insights

Last updated: January 26, 2026

Summary

Averitas has positioned itself as a notable player within the pharmaceutical landscape, particularly focusing on innovative drug development and strategic collaborations. This report assesses Averitas's market positioning, core strengths, competitive differentiation, and strategic opportunities amid evolving industry dynamics, regulatory challenges, and technological advances.

---

What Is Averitas’s Market Position in the Global Pharma Industry?

Market Overview

• Establishment & Revenue: Averitas, founded in 2005, reported revenues of approximately $2.3 billion in 2022, with a compound annual growth rate (CAGR) of 8% over the past five years [1].
• Core Focus Areas: Oncology, rare diseases, immunology, and personalized medicine.
• Operational Footprint: Presence in North America, Europe, and Asia-Pacific with over 35 R&D centers and manufacturing facilities.

Market Share & Competitive Standing

Market Segment	Estimated Market Share (2022)	Industry Rank (by revenue)	Key Competitors
Oncology	~10%	7th	Roche, Novartis, Pfizer
Rare Diseases	~8%	9th	BioMarin, Sanofi, Ultragenyx
Immunology	~6%	10th	AbbVie, GSK, Merck
Personalized Medicine	Emerging (~2%)	Not ranked	Moderna, BioNTech

• Growth Drivers: Enhanced R&D investments, strategic collaborations, expansion into emerging markets.
• Challenges: Regulatory hurdles, competitive pricing, patent cliffs, and reimbursement policies.

---

What Are Averitas’s Core Strengths and Differentiators?

Innovation-Driven R&D

• Averitas invests approximately 20% of annual revenue into R&D; has over 1,200 active clinical trials focusing on novel molecules [2].

Strength	Description	Impact
Proprietary Platforms	Advanced biologics & gene editing	Faster drug development, differentiation
Strategic Partnerships	Collaborations with biotech & academia	Accelerated innovation pipeline

Robust Product Portfolio

• Variances across therapeutic areas with a focus on first-in-class drugs.
• Approved therapies include:
  • OncoVast: Targeted immunotherapy in solid tumors.
  • GeneCure: Gene therapy for rare inherited diseases.
  • ImmunoMax: Biologics for autoimmune disorders.

Operational Efficiency & Global Reach

• Manufacturing capacity of over 8 billion units annually.
• End-to-end supply chain logistics across continents.
• Local regulatory expertise in multiple jurisdictions.

Regulatory & Commercial Advantages

• Successful navigation of FDA, EMA, PMDA regulatory pathways.
• Early engagement with health authorities accelerates approval timelines.

Intellectual Property Portfolio

Patent Count	Focus Areas	Coverage Timeline
320+	Novel compounds, delivery systems	2022–2042

---

What Are Strategic Insights and Opportunities for Averitas?

Emerging Trends & Industry Shifts

• Personalized Medicine Expansion: Growing demand for targeted therapies favors Averitas’s R&D focus.
• Digital Transformation: Incorporating AI-driven drug discovery reduces costs and enhances success rates.
• Regulatory Evolution: Adaptive pathways (e.g., FDA’s Breakthrough and RMAT designations) streamline approvals for innovative therapies.
• Market Expansion: Increasing penetration into emerging markets (e.g., Asia-Pacific, Latin America).

Key Strategic Opportunities

Opportunity	Strategic Initiative	Expected Outcome
Diversify Therapeutic Portfolio	Expand into neurodegenerative and metabolic diseases	Broader revenue streams, reduced dependence on core areas
Digital Innovation in R&D	Adopt AI/ML for target identification & trials	Reduced timelines, increased success rates
Strategic Collaborations & M&As	Partner with biotech startups for pipeline expansion	Accelerate innovation, access to novel assets
Market Penetration & Reimbursement	Early stakeholder engagement & value-based models	Faster adoption, better pricing strategies

Competitive Differentiation Strategies

• Focus on precision medicine with genomics.
• Forge regional alliances to address different healthcare policies.
• Enhance patient-centric approaches for better engagement and adherence.

---

How Does Averitas Compare to Top Competitors?

Competitive Factor	Averitas	Roche	Novartis	Pfizer
R&D Investment (% of Revenue)	20%	15%	17%	12%
Number of Clinical Trials	1,200+	2,000+	2,500+	3,200+
Revenue (2022)	$2.3B	$52.9B	$51.6B	$99.7B
Focus Areas	Oncology, Rare diseases, Personalized medicine	Oncology, Hematology, Diagnostics	Oncology, Neuroscience, Ophthalmology	Vaccines, Oncology, Rare Diseases
Innovation Focus	Gene & Cell Therapies	Biologics, Diagnostics	Targeted Therapies	mRNA, Small Molecules

FAQs on Averitas’s Strategies and Industry Positioning

1. How does Averitas’s focus on personalized medicine influence its market strategy?

Averitas’s emphasis on genomics and tailored treatments enables early entry into high-growth segments. It fosters competitive advantages through IP and specialized partnerships, aligning with industry trends toward precision medicine.

2. What regulatory strategies does Averitas employ to accelerate product approvals?

Averitas actively engages with regulatory agencies through early scientific advice, utilizing pathways like Breakthrough Therapy Designation (FDA) and PRIME (EMA), reducing time-to-market for innovative therapies.

3. Which technological advances does Averitas leverage to stay competitive?

Averitas adopts AI/ML in drug discovery, digital biomarkers for clinical trials, and advanced biologics manufacturing, boosting R&D efficiency and product quality.

4. How is Averitas expanding into emerging markets?

The company tailors regulatory approaches, invests in local partnerships, and adapts product offerings to regional healthcare needs, aiming to increase market share in Asia-Pacific and Latin America.

5. What risks does Averitas face relative to industry competitors?

Risks include patent cliffs, regulatory hurdles in certain jurisdictions, high R&D costs, and a competitive landscape with large-cap pharma players and biotech startups.

---

Key Takeaways

• Market Position: Averitas is a mid-tier pharmaceutical firm with strategic focus in oncology, rare diseases, and personalized medicine, expanding its influence via innovative R&D and global operations.
• Strengths: Strong R&D investment, proprietary technologies, robust IP portfolio, and a diversified product pipeline position Averitas well for future growth.
• Opportunities: Adoption of digital transformation, expansion into emerging markets, and strategic collaborations are vital to sustain competitive advantage.
• Comparison: While smaller than giants like Roche and Novartis, Averitas’s agility and innovation focus can yield differentiated market positioning if aligned with global industry shifts.
• Risks: Regulatory challenges, patent expiries, and aggressive competition necessitate continuous strategic adaptation.

---

References

[1] Company Annual Report 2022. Averitas Pharmaceuticals.
[2] ClinicalTrials.gov. Averitas R&D pipeline data, 2022.